A Prospective Study to Monitor for Tuberculosis During Anti-tumour Necrosis Factor Therapy in Patients With Inflammatory Bowel Disease and Immune-mediated Inflammatory Diseases

@article{Lee2018APS,
  title={A Prospective Study to Monitor for Tuberculosis During Anti-tumour Necrosis Factor Therapy in Patients With Inflammatory Bowel Disease and Immune-mediated Inflammatory Diseases},
  author={Choon Kin Lee and Sunny Hei Wong and Grace Chung Yan Lui and Whitney Tang and Lai S Tam and Margaret Ip and Esther Hiu Yee Hung and Minhu Chen and Justin C.Y. Wu and Siew Chien Ng},
  journal={Journal of Crohn's and Colitis},
  year={2018},
  volume={12},
  pages={954–962}
}
Background Biologic therapies have revolutionised the treatment of immune-mediated diseases including inflammatory bowel disease [IBD] and rheumatological disorders. However, biologic treatments are associated with an increased risk of reactivation of latent tuberculosis. Data from regular monitoring for latent tuberculosis infection [LTBI] during biologic treatment are lacking. Methods Consecutive patients eligible for biologic therapies were screened for LTBI and prospectively followed up… 
View on Wolters Kluwer
academic.oup.com
17 Citations
Highly Influential Citations
2
Background Citations
3

17 Citations

Frequency of Positive Conversion of Interferon-Gamma Release Assay Results Among Patients With Inflammatory Bowel Disease Treated With Non-tumor Necrosis Factor Inhibitors
TLDR
Positive IGRA conversion among IBD patients treated with vedolizumab and/or ustekinumab appears to occur somewhat frequently, but its clinical implications remain to be elucidated.
Approach to Latent Tuberculosis Infection Screening Before Biologic Therapy in IBD Patients: PPD or IGRA?
TLDR
It has been shown that anti-TNF-α treated patients have a 14-fold increased risk of tuberculosis (TB) infection/reactivation compared with healthy controls.
Tuberculosis despite latent infection screening and treatment in patients receiving TNF inhibitor therapy
TLDR
Tuberculosis still develops in patients treated with tumor necrosis factor (TNF)–inhibitors despite prior screening and treatment for latent tuberculosis infection (LTBI).
Active tuberculosis in inflammatory bowel disease patients under treatment from an endemic area in Latin America
TLDR
Treatment with anti-TNFα increased the risk of active TB in IBD patients from an endemic area in Latin America and the time from the beginning of the treatment to the active TB diagnosis suggests a new TB infection.
Conversion and Reversion Rates of Tuberculosis Screening Assays in Patients With Rheumatic Diseases and Negative Baseline Screening Under Long-Term Biologic Treatment
TLDR
The findings do not support routine serial TB retesting in biologic-treated patients with rheumatic diseases in the absence of TB risk factors and develop conversion of at least 1 screening test during long-term biologic treatment.
Review article: latent tuberculosis in patients with inflammatory bowel diseases receiving immunosuppression—risks, screening, diagnosis and management
TLDR
Current guidelines on the testing and treatment of LTBI in patients with IBD are haphazard with a paucity of evidence, according to the World Health Organization.
Recommendations of the Spanish Working Group on Crohn's Disease and Ulcerative Colitis (GETECCU) on screening and treatment of tuberculosis infection in patients with inflammatory bowel disease
Stringent screening strategy significantly reduces reactivation rates of tuberculosis in patients with inflammatory bowel disease on anti‐TNF therapy in tuberculosis endemic region
Anti‐tumor necrosis factor (anti‐TNF) therapy use in patients with inflammatory bowel disease (IBD) leads to an increased risk of tuberculosis (TB) reactivation despite latent tuberculosis (LTB)…
Tuberculosis screening and management of latent tuberculosis infection prior to biologic treatment in patients with immune‐mediated inflammatory diseases: A longitudinal population‐based analysis using claims data
TLDR
Adherence to the recommended practice of screening for tuberculosis before treating with biologic agents in patients with immune‐mediated inflammatory diseases (IMIDs) in Japan is identified.
Useful message in choosing optimal biological agents for patients with autoimmune arthritis.
...
...

References

SHOWING 1-10 OF 48 REFERENCES
Performance of Interferon-gamma Release Assay for Tuberculosis Screening in Inflammatory Bowel Disease Patients
TLDR
IGRA results are negatively impacted by immunosuppressive therapy, and current guidelines suggesting TB screening before anti-tumor necrosis factor therapy may be inadequate in patients already on immunosppressive drugs are suggested.
Risk of developing tuberculosis under anti-TNF treatment despite latent infection screening.
PTU-050 Addressing The Issue of Indeterminate Interferon Gamma Release Assays Prior to Biologic Therapy in Patients with Inflammatory Bowel Disease Patients
TLDR
Almost one third of IBD patients had an indeterminate IGRA result with half of those having a second ind determinate result, which supports risk stratification with more weight added to the risk than IGRA alone.
Effectiveness of recommendations to prevent reactivation of latent tuberculosis infection in patients treated with tumor necrosis factor antagonists.
TLDR
Strategies to treat latent TB infection that are tailored to the at-risk population can effectively and safely lessen the likelihood of active TB in patients treated with TNF antagonists.
Serial Interferon-gamma Release Assays for the Diagnosis of Latent Tuberculosis Infection in Patients Treated with Immunosuppressive Agents
TLDR
In patients receiving immunosuppressive agents, both IGRA conversions and reversions were observed, and Serial IGRA testing may not be needed in patients with a positive initial IGRA result showing high IFN-γ levels, because of high consistency in the test results.
Performance of interferon‐gamma release assays in patients with inflammatory bowel disease: A systematic review and meta‐analysis
TLDR
While it remains difficult to determine superiority between the IGRAs and the TST, both are negatively affected by IST and it is imperative that all patients receive screening prior to anti‐TNF therapy.
Tuberculosis associated with infliximab, a tumor necrosis factor alpha-neutralizing agent.
TLDR
Active tuberculosis may develop soon after the initiation of treatment with infliximab, and physicians should screen patients for latent tuberculosis infection or disease before prescribing the drug.
Drug-specific risk of tuberculosis in patients with rheumatoid arthritis treated with anti-TNF therapy: results from the British Society for Rheumatology Biologics Register (BSRBR)
TLDR
The rate of TB in patients with RA treated with anti-TNF therapy was three- to fourfold higher in patients receiving INF and ADA than in those receiving ETA.
Second European evidence-based consensus on the prevention, diagnosis and management of opportunistic infections in inflammatory bowel disease.
Indeterminate QuantiFERON-TB Gold Increases Likelihood of Inflammatory Bowel Disease Treatment Delay and Hospitalization.
TLDR
Indeterminate QFTG results were associated with delayed anti-TNF initiation and subsequent hospitalization, and systemic corticosteroid use and hospitalization wereassociated with an indeterminateQFTG result.
...
...